n August 2018, the Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) stating the application required additional data to further assess the efficacy and tolerability of dasotraline.
Dulaglutide reduces binge eating behaviors in patients with type 2 diabetes and binge eating disorder and may be a preferred treatment for this group.
Researchers assessed the incidence of various hematologic disorders in patients with bulimia nervosa and anorexia nervosa.
Mediation analyses identified food addiction and psychological distress as significant mediators of the association between weight-related self-stigma and binge eating.
Mental health outcomes do not appear to improve for obese adolescents undergoing Roux-en-Y gastric bypass.
Findings suggest that identifying children with specific eating behaviors might be a promising approach for targeted intervention to prevent progression eating disorders in adolescence.
Patients may be at risk for increased comorbidity burden after a diagnosis of binge eating disorder.
Dasotraline may reduce compulsions and obsessive thoughts in adults with binge eating disorder.
Binge eating and purging were found to be common among adolescents and seen at a higher rate in female adolescents.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for dasotraline (Sunovion) in the treatment of binge eating disorder.
